Who Is at Risk for an Inhibitor?

Who Is at Risk for an Inhibitor?

Some people with hemophilia and VWD type 3 will develop inhibitors.

Get the Facts About Inhibitors

• During their lifespan, about 1 in 5 people with hemophilia A and about 3 in 100 people with hemophilia B will develop an inhibitor.
• Blacks and Hispanics are twice as likely as Whites to develop inhibitors.
• Inhibitors can occur at any age, but children younger than age 2 years are at greatest risk.
• People with hemophilia who develop an inhibitor are twice as likely to be hospitalized for a bleeding complication, and they are at increased risk of death.
• The treatment for bleeding is not as effective for people with hemophilia who have an inhibitor.
• Managing bleeding episodes can be challenging and expensive when patients have an inhibitor. CDC’s surveillance (healthcare monitoring programs) helps to track complications and inform best practices for those living with hemophilia.